The Fly | NMRA

Today

Neumora Therapeutics reports pre-clinical toxicology results from NMRA-215 study

NMRA

7:07 AM

Over a week ago

Neumora Therapeutics price target lowered by $2 at RBC Capital, here's why

NMRA

Jul 13, 9:20 AM

Neumora Therapeutics price target lowered by $2 at Mizuho, here's why

NMRA

Jun 18, 8:11 AM

Neumora Therapeutics price target lowered by $3 at Needham, here's why

NMRA

Jun 16, 7:22 AM

Neumora Therapeutics price target lowered by $11 at H.C. Wainwright, here's why

NMRA

Jun 16, 6:06 AM

Clear Street says Neumora failed trial does not impact LB Pharmaceuticals LB-102

Jun 15, 6:30 PM

Neumora Therapeutics announces KOASTAL studies miss primary endpoint

NMRA

Jun 15, 8:53 AM

Neumora Therapeutics reports Q1 EPS (30c), consensus (31c)

NMRA

May 7, 7:20 AM

Neumora Therapeutics management to meet with Piper Sandler

NMRA

Apr 2, 10:30 AM

What You Missed On Wall Street On Monday

+27

Mar 30, 4:30 PM

Midday Fly By: Sysco buying Restaurant Depot, Uber to acquire Blacklane

+25

Mar 30, 12:01 PM

Neumora Therapeutics reports Q4 EPS (35c), consensus (33c)

NMRA

Mar 30, 6:55 AM

Neumora Therapeutics management to meet virtually with Needham

NMRA

Mar 2, 1:04 PM

Neumora upgraded to Outperform from Market Perform at William Blair

NMRA

Feb 17, 6:00 AM

Neumora Therapeutics initiated with bullish view at Leerink, here's why

NMRA

Jan 12, 5:20 AM

Neumora Therapeutics price target raised by $1 at Mizuho, here's why

NMRA

Jan 6, 8:04 AM

Neumora Therapeutics highlights 2026 pipeline strategy

NMRA

Jan 5, 6:37 AM

Neumora Therapeutics announces results from NMRA-511 Phase 1b study

NMRA

Jan 5, 6:35 AM

What You Missed On Wall Street On Monday

+37

Dec 1, 4:34 PM

Midday Fly By: Nvidia invests in Synopsys, U.S. strikes pharma deal with UK

+35

Dec 1, 12:00 PM

Neumora Therapeutics just upgraded at RBC Capital, here's why

NMRA

Dec 1, 5:35 AM

Neumora Therapeutics price target raised by $1 at Stifel, here's why

NMRA

Nov 17, 7:25 AM

LB Pharmaceuticals appoints Kaya Pai Panandiker as CCO

Nov 12, 8:14 AM

Proprietary Precision Neuroscience Platform: Neumora leverages its unique platform that integrates data science, genomics, and clinical insights to identify and validate novel targets and develop precision therapeutics for brain disorders.

Targeted Disease Approach: The company focuses on specific patient populations and underlying disease mechanisms in neurological and psychiatric disorders, utilizing biomarkers to increase the likelihood of therapeutic success and reduce development risk.

Robust and Diverse Pipeline: Neumora possesses a multi-asset pipeline with candidates addressing various neurological and psychiatric conditions across different stages of development, diversifying risk and potential market opportunities.

Clinical Trial Failure Risk: All drug candidates are in various stages of clinical development and may fail to demonstrate efficacy or safety, leading to no marketable products.

Regulatory Approval Risk: Even successful clinical trials do not guarantee regulatory approval from health authorities like the FDA or EMA, which could prevent commercialization.

Competition Risk: Other companies may develop superior or faster-to-market treatments for the target indications, reducing Neumora's potential market share and profitability.

Charts

Clinical Trial Failure Risk: All drug candidates are in various stages of clinical development and may fail to demonstrate efficacy or safety, leading to no marketable products.

Regulatory Approval Risk: Even successful clinical trials do not guarantee regulatory approval from health authorities like the FDA or EMA, which could prevent commercialization.

Competition Risk: Other companies may develop superior or faster-to-market treatments for the target indications, reducing Neumora's potential market share and profitability.